Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVP-2102-R
- Development stage
- Unknown
- Lead developer
- Navipharm
- Administration
- Oral
01
Overview
NVP-2102-R is an investigational drug developed by Navipharm and NVP Healthcare. It has been studied in a Phase 1 clinical trial to compare its pharmacokinetics and safety profile with that of a related compound, NVP-2102, in healthy subjects. The specific mechanism of action, molecular target(s), modality, and therapeutic indication for NVP-2102-R have not been disclosed publicly as of June 2025. The available data indicate that the drug is administered orally and is being evaluated primarily for its pharmacokinetic properties rather than for treatment of a specific disease at this stage[1][6][8].
- Other names
- NVP 2102 RNVP2102 RNVP-2102 R
Beyond the preview
Go deeper on NVP-2102-R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVP-2102-R.